Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

f 2009, including $1.3 million for lease termination activities and $0.6 million for employee termination costs related to the March 2009 restructuring. For the three and six months ended June 30, 2008, restructuring charges were $4.9 million and $5.2 million, relating primarily to the June 2008 restructuring.
  • Other expense of $21.0 million and $21.1 million was recorded in the three and six months ended June 30, 2009, primarily resulting from non-cash charges of $21.0 million related to the accounting for the private placement.
  • Sunesis reported net losses of $22.9 million and $31.2 million for the three and six months ended June 30, 2009, compared to reported net losses of $13.6 million and $23.2 million for the same periods in 2008.
  • Cash used in operations was $5.8 million and $12.4 million for the three and six month periods ending June 30, 2009, compared to $8.2 million and $18.7 million for the same periods in 2008.
  • About Voreloxin

    Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

    About Acute Myeloid Leukemia

    AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates tha
    '/>"/>

    SOURCE Sunesis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
    2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
    4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
    5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
    6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
    7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
    8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
    9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
    10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
    11. Sunesis to Present at Upcoming Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... YORK and SANTA CLARA, Calif. ... Corp. (NASDAQ: WBMD ), the leading source ... new WebMD/Medscape survey that provide novel insights ... in aiding diagnosis and care.  Dr. Eric Topol ... and digital medicine, who serves as both Editor-in-Chief of ...
    (Date:9/22/2014)... researchers at the USC Viterbi School of Engineering, ... microfluidic system quickly and cheaply by simply snapping ... systems are used in many fields including engineering, ... of fluids for use in applications such as ... testing, and synthetic chemistry. Traditionally, microfluidic devices are ...
    (Date:9/22/2014)... cells (CTCs) in a mouse model of pancreatic cancer ... of CTCs, including significant differences from the primary tumor ... In their study reported in the Sept. 25 ... Massachusetts General Hospital (MGH) Cancer Center identified several different ... may prove to be targets for improved treatment of ...
    (Date:9/22/2014)... of Minnesota electrical engineering researchers have developed a ... demonstrates mechanical transportation of light. The discovery could ... efficient optical devices for computation and communication. , ... and computer engineering assistant professor Mo Li and ... online and will appear in the October issue ...
    Breaking Biology Technology:WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Engineers show light can play seesaw at the nanoscale 2
    ... and PHILADELPHIA, July 4 ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), ... earnings on,Thursday 31 July 2008, Results press ... BST / 07:00 EDT Investor meeting and conference ... Investor & Analyst meeting and conference call:, Angus ...
    ... Research Group has,released results from aboratory testing ... at Oregon State University which,demonstrated the Eniva ... for human cells. This third party testing ... effort to further identify,mechanisms by which the ...
    ... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today announced that ... its cash burn rate. As previously,announced, the Company ... acquisitions and mergers. In conjunction with this,process, the ... its VP,series of drugs, and has determined that ...
    Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2Vasogen Provides Corporate Update 2
    (Date:9/21/2014)... new strains of bacteria have emerged that resist even ... drug-resistant forms of tuberculosis and staphylococcus, infect more than ... Despite the urgent need for new treatments, scientists have ... past decade. , MIT engineers have now turned a ... system that can disable any target gene, they have ...
    (Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
    (Date:9/19/2014)... University of Oklahoma biology professor will study the unique ... that could eventually benefit people,s health. The OU ... the energy required to produce the signals used to ... electric signals at a rate of 500-600 discharges a ... for the electric fish are extreme, but necessary for ...
    Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
    ... Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) ... genetics of ALS. Amyotrophic lateral sclerosis (ALS), also ... fatal neurological disease involving the degeneration and death of ... the most common neuromuscular diseases worldwide, affecting as roughly ...
    ... sturgeons, more caviar will be exported from Caspian Sea ... of unacceptably permissive new trade quotas announced Thursday by ... Most sturgeon species are endangered and some, like beluga ... damage this ancient fish,s chance of recovery and survival, ...
    ... New research* shows that while engineered nanomaterials can ... food chain from single celled organisms to higher ... and there was no evidence of the nanomaterials ... results observed by researchers from the National Institute ...
    Cached Biology News:New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4Research measures movement of nanomaterials in simple model food chain 2
    ... Smith et.al. (1997) • Contains ... current biochemistry & molecular biology, ... headwords. Entries give details of ... in which they are involved ...
    ... Dunbar (1994) • This book describes ... methods for preparing samples for protein ... radiometric and bioluminescence-enhanced detection systems are ... the detection and characterization of glycoprotein ...
    ... by John M. Walker (1996) • ... analytical techniques for studying proteins and ... contains detailed, step-by-step instruction, timesaving troubleshooting ... comprehensive lists of reagents and suppliers. ...
    ... PhastGel DNA Silver Staining Kit, ... polyacrylamide gels.Separate proteins and peptides on ... time and improve reproducibility with precast ... detection sensitivity comparable to that of ...
    Biology Products: